Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test

Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed a supply and distribution agreement for Genetic Analysis’s GA-map™ clinical test for gut dysbiosis.

The patented GA-map™ technology is used as an aide in the diagnosis and management of irritable bowel syndrome and inflammatory bowel disease.

Dysbiosis is a microbial imbalance or maladaptation on or inside the body and is most commonly reported as a condition in the digestive tract. It has been associated with illnesses, such as inflammatory bowel disease and other chronic diseases.

“We are delighted to enter into this agreement with Bio-Rad,” said Ronny Hermansen, CEO of Genetic Analysis.During the past year, the body of evidence supporting the use of GA-maphas grown considerably. Bio-Rad has the market knowledge and necessary resources to accelerate the uptake of this technology by clinicians worldwide. We look forward to further developing our product portfolio with Bio-Rad’s continuing support.”

“We welcome the opportunity to partner with Genetic Analysis,” said John Hertia, Bio-Rad Executive Vice President, President, Clinical Diagnostics Group.  “With the GA-map technology, we will be able to offer products that can analyze the microbiome associated with gut dysbiosis, which affects the quality of life of many patients around the world and can result in serious health problems.”

Source: http://www.bio-rad.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bio-Rad Laboratories. (2017, December 13). Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/20171213/Genetic-Analysis-and-Bio-Rad-enter-into-supply-and-distribution-agreement-for-GA-map-clinical-test.aspx.

  • MLA

    Bio-Rad Laboratories. "Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test". News-Medical. 19 April 2024. <https://www.news-medical.net/news/20171213/Genetic-Analysis-and-Bio-Rad-enter-into-supply-and-distribution-agreement-for-GA-map-clinical-test.aspx>.

  • Chicago

    Bio-Rad Laboratories. "Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test". News-Medical. https://www.news-medical.net/news/20171213/Genetic-Analysis-and-Bio-Rad-enter-into-supply-and-distribution-agreement-for-GA-map-clinical-test.aspx. (accessed April 19, 2024).

  • Harvard

    Bio-Rad Laboratories. 2017. Genetic Analysis and Bio-Rad enter into supply and distribution agreement for GA-map clinical test. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/20171213/Genetic-Analysis-and-Bio-Rad-enter-into-supply-and-distribution-agreement-for-GA-map-clinical-test.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies